Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O75496
UPID:
GEMI_HUMAN
Alternative names:
-
Alternative UPACC:
O75496; B3KMM8; Q9H1Z1
Background:
Geminin, encoded by the gene with accession number O75496, plays a crucial role in DNA replication and cell cycle regulation. It inhibits DNA replication by preventing the MCM complex's incorporation into the pre-replication complex and is degraded during the mitotic phase. Geminin also modulates histone acetyltransferase activity of KAT7/HBO1, affecting histone H4 acetylation and DNA replication licensing.
Therapeutic significance:
Geminin's involvement in Meier-Gorlin syndrome 6, characterized by growth retardation and skeletal anomalies, underscores its potential as a therapeutic target. Understanding the role of Geminin could open doors to potential therapeutic strategies.